As of 2025-07-01, the EV/EBITDA ratio of Karyopharm Therapeutics Inc (KPTI) is -3.57. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KPTI's latest enterprise value is 251.94 mil USD. KPTI's TTM EBITDA according to its financial statements is -70.58 mil USD. Dividing these 2 quantities gives us the above KPTI EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.1x - 10.6x | 8.1x |
| Forward P/E multiples | 11.0x - 16.2x | 11.3x |
| Fair Price | (114.63) - (111.03) | (104.01) |
| Upside | -2711.1% - -2629.3% | -2469.2% |
| Date | EV/EBITDA |
| 2025-06-27 | -3.57 |
| 2025-06-26 | -3.58 |
| 2025-06-25 | -3.58 |
| 2025-06-24 | -3.60 |
| 2025-06-23 | -3.56 |
| 2025-06-20 | -3.57 |
| 2025-06-18 | -3.58 |
| 2025-06-17 | -3.57 |
| 2025-06-16 | -3.59 |
| 2025-06-13 | -3.57 |
| 2025-06-12 | -3.57 |
| 2025-06-11 | -3.57 |
| 2025-06-10 | -3.57 |
| 2025-06-09 | -3.55 |
| 2025-06-06 | -3.58 |
| 2025-06-05 | -3.55 |
| 2025-06-04 | -3.56 |
| 2025-06-03 | -3.55 |
| 2025-06-02 | -3.54 |
| 2025-05-30 | -3.55 |
| 2025-05-29 | -3.59 |
| 2025-05-28 | -3.58 |
| 2025-05-27 | -3.59 |
| 2025-05-23 | -3.59 |
| 2025-05-22 | -3.60 |
| 2025-05-21 | -3.61 |
| 2025-05-20 | -3.66 |
| 2025-05-19 | -3.66 |
| 2025-05-16 | -3.68 |
| 2025-05-15 | -3.70 |
| 2025-05-14 | -3.63 |
| 2025-05-13 | -3.63 |
| 2025-05-12 | -3.78 |
| 2025-05-09 | -3.77 |
| 2025-05-08 | -3.78 |
| 2025-05-07 | -3.78 |
| 2025-05-06 | -3.80 |
| 2025-05-05 | -3.90 |
| 2025-05-02 | -3.93 |
| 2025-05-01 | -3.86 |
| 2025-04-30 | -3.86 |
| 2025-04-29 | -3.81 |
| 2025-04-28 | -3.78 |
| 2025-04-25 | -3.72 |
| 2025-04-24 | -3.76 |
| 2025-04-23 | -3.80 |
| 2025-04-22 | -3.77 |
| 2025-04-21 | -3.69 |
| 2025-04-17 | -3.64 |
| 2025-04-16 | -3.57 |